# US 2026/0165980 A1 · Lymphatic endothelial cell-specific lipid nanoparticle and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0165980 A1
- Document ID: US20260165980A1
- Status: Published application
- Kind: A1
- Application number: 19/122,926
- Filed: 2023-10-20
- Published: 2026-06-18
- Earliest claimed: 2022-10-21
- Assignees: Georgia Tech Research Corporation; The Regents of the University of Colorado, a body corporate
- Applicants: Georgia Tech Research Corporation; The Regents of the University of Colorado, A Body Corporate
- Inventors: Eleftheria MICHALAKI; James DAHLMAN; Brandon DIXON; Beth TAMBURINI
- Web page: https://patentgrep.com/patent/US20260165980A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K 48/0041: {the non-active part being polymeric}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/6056: {Antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to lymphatic endothelial cell (LEC)-specific lipid nanoparticle comprising a sterol, an ionizable lipid, a PEGylated lipid, and a phospholipid. Also disclosed herein are compositions comprising the LEC-specific lipid nanoparticle and a therapeutic agent. The present disclosure further relates to methods of delivering an agent to a lymphatic system in a subject, comprising administering to the subject an effective amount of the composition of the LEC-specific lipid nanoparticle and therapeutic agent.

## Claims

### Claim 1

A lymphatic endothelial cell-specific lipid nanoparticle comprising a sterol, an ionizable lipid, a PEGylated lipid, and a phospholipid.

### Claim 2 (depends on 1)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 1, further comprising an alcohol.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 1, wherein the phospholipid is 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE):
or
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC):

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 1, wherein the sterol comprises cholesterol.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 1, wherein the ionizable lipid comprises
wherein each R is independently a substituted or unsubstituted C8-C18 alkyl.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 1, wherein each R is independently an unsubstituted C8-C18 alkyl.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 1, wherein the ionizable lipid is cKK-E12:

### Claim 15 (depends on 1)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 1, wherein the PEGylated lipid is C14PEG2000:

### Claim 16 (depends on 1)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 1, wherein a molar ratio of the ionizable lipid to the other components is from 25% to 60%.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 1, wherein a molar ratio of the phospholipid to the other components is from 0.1% to 8%.

### Claim 19 (depends on 1)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 1, wherein a molar ratio of the PEGylated lipid to the other components is from 8% to 45%.

### Claim 20 (depends on 2)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 2, comprising from 30% to 50% v/v alcohol, from 12% to 25% v/v of the ionizable lipid, from 5% to 18% v/v of the sterol, from 5% to 8% v/v of the PEGylated lipid, and from 5% to 35% v/v of the phospholipid.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 2)

The lymphatic endothelial cell-specific lipid nanoparticle of claim 2, comprising:
44.88% v/v ethanol, 24.88% v/v cKK-E12, 13.56% v/v cholesterol, 6.76% v/v C14PEG2000, and 9.92% v/v DSPC, or
37.04% v/v ethanol, 17.04% v/v cKK-E12, 6.84% v/v cholesterol, 6.6% v/v C14PEG2000, and 32.48% v/v DOPE, or
43.96% v/v ethanol, 23.96% v/v cKK-E12, 5.35% v/v cholesterol, 6.18% v/v C14PEG2000, and 20.55% v/v DOPE.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28 (depends on 1)

A composition comprising: the lymphatic endothelial cell-specific lipid nanoparticle of claim 1 and a therapeutic agent, wherein the therapeutic agent comprises a nucleic acid, a peptide, or a small molecule.

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31 (depends on 28)

The composition of claim 28, wherein the nucleic acid, peptide, or small molecule comprises, a VEGF protein, a nucleotide encoding a VEGF protein, or a fragment thereof.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 28)

A method of treating a lymphatics-associated disorder in a subject, comprising administering to the subject a therapeutically effective amount of the composition of claim 28.

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43 (depends on 28)

A method of enhancing lymphangiogenesis in a subject, comprising administering to the subject a therapeutically effective amount of the composition of claim 28.

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47 (depends on 1)

An mRNA vaccine comprising the lymphatic endothelial cell-specific lipid nanoparticle of claim 1 and an mRNA disposed therewithin.

### Claim 48

(canceled)

### Claim 49 (depends on 47)

A method of preventing or treating a disorder or an infection in a subject, comprising administering to the subject a therapeutically effective amount of the mRNA vaccine of claim 47.

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52 (depends on 28)

A pharmaceutical composition comprising the composition of claim 28 and a pharmaceutically acceptable carrier.
